# V1 Empirics Check — mistralai/mistral-large-2512 (Variant A)

**Model:** mistralai/mistral-large-2512
**Variant:** A
**Date:** 2026-03-30T22:19:17.839179

---

### 1. Idea Fidelity

The paper largely adheres to the original idea manifest but deviates in several important ways that weaken its execution:

1. **Sample Size and Scope**: The manifest promised analysis of 80M+ records (2016-2024), but the paper uses only 433K records (2018-2024) from the first 160K API calls per year. This is a critical limitation—bunching estimation requires large samples to precisely estimate counterfactual densities, and the paper’s sample may not be representative of the full distribution. The manifest’s "smoke test" showed density jumps around the threshold, but the paper’s smaller sample may lack the power to detect subtle bunching patterns.

2. **Identification Strategy**: The manifest emphasized a *moving-threshold bunching estimator* with cross-year validation, but the paper’s pooled estimate centers each year’s distribution on its own threshold without fully leveraging the time-series variation. The manifest’s "cross-year validation" (tracking the censoring point across years) is underdeveloped in the paper. The placebo tests (Table 6) are a step in the right direction but could be expanded to exploit the full panel structure (e.g., event-study plots of bunching around threshold changes).

3. **Mechanism Tests**: The manifest proposed linking to Medicare Part D prescribing data to test mechanisms, but this is entirely absent from the paper. The heterogeneity analysis by payment type is a good start, but the lack of prescribing outcomes weakens the paper’s claim about the "informational blind spot’s" real-world consequences.

4. **Novelty**: The paper correctly notes the lack of prior bunching work on Open Payments thresholds, but it does not engage deeply with the broader literature on disclosure avoidance (e.g., tax evasion, lobbying disclosure) or the welfare implications of threshold-based reporting rules. The manifest’s "bigger picture" (welfare implications for transparency mandates) is underdeveloped.

### 2. Summary

The paper uses bunching estimation to quantify how the CPI-indexed per-transaction reporting threshold in the CMS Open Payments database censors small pharmaceutical payments to physicians. Using 433K records (2018-2024), it finds significant missing mass just below the threshold, concentrated in food/beverage payments, suggesting manufacturers strategically size payments to avoid disclosure. The results imply that the public database underrepresents informal industry-physician interactions, with potential implications for research on conflicts of interest.

### 3. Essential Points

**The authors must address the following three issues to make the paper publishable:**

1. **Sample Representativeness and Power**:
   - The paper’s sample (first 160K records/year) is likely non-random and may not reflect the true distribution of payments. The authors must:
     - Justify why the API’s pagination order is random (or test for selection bias, e.g., by comparing summary stats to full-year data if available).
     - Report results using the full dataset (or a random subsample) if possible. If not, acknowledge this as a major limitation and discuss how it might bias the bunching estimates (e.g., if small payments are underrepresented in early API pages).
     - Conduct power calculations to show whether the sample size is sufficient to detect the observed effect sizes.

2. **Identification and Cross-Year Validation**:
   - The manifest’s key innovation was the *moving threshold* design, but the paper does not fully exploit this. The authors must:
     - Present a formal test of whether the bunching point tracks the threshold over time (e.g., regress the estimated bunching location on the threshold value, with year fixed effects).
     - Show event-study plots of bunching around threshold changes (e.g., density histograms for each year, centered on the threshold, with the counterfactual overlaid).
     - Clarify whether the pooled estimate is weighted by year-specific sample sizes or counterfactual densities (the current approach is unclear).

3. **Mechanism and Welfare Implications**:
   - The paper claims the censoring gap has "direct welfare implications" but provides no evidence on how it affects prescribing or research using Open Payments data. The authors must:
     - Link to Medicare Part D data (as promised in the manifest) to test whether physicians receiving below-threshold payments prescribe differently than those with no recorded payments.
     - Discuss the welfare trade-offs of the threshold (e.g., compliance costs vs. informational value) and whether the observed avoidance behavior justifies policy changes (e.g., lowering the threshold to $1).

### 4. Suggestions

**Data and Sample Improvements:**
- **Full Dataset**: If the API limits are binding, consider using the full downloadable datasets (available as CSV files) for at least one year to validate the API sample’s representativeness.
- **Bandwidth Selection**: The paper uses a fixed $3 bandwidth, but the optimal bandwidth may vary by year (e.g., wider for years with fewer observations). Report results using data-driven bandwidth selection (e.g., Calonico et al., 2017).
- **Exclusion Region**: The exclusion region ($1.5 below, $0.5 above) is arbitrary. Test sensitivity to alternative definitions (e.g., symmetric exclusion) and report results with and without exclusion.

**Methodological Clarifications:**
- **Counterfactual Fit**: Show the polynomial counterfactual fit graphically for each year (as in Saez, 2010) to demonstrate that the missing mass is not an artifact of poor fit.
- **Bootstrap Details**: Clarify whether the Poisson bootstrap resamples payments or bins, and whether it accounts for within-physician or within-manufacturer clustering.
- **Normalization**: The normalized bunching estimate ($\hat{b}$) is sensitive to the counterfactual density at the threshold. Report raw excess mass counts alongside $\hat{b}$ to aid interpretation.

**Heterogeneity and Robustness:**
- **Manufacturer-Level Analysis**: Test whether bunching varies by manufacturer size or product portfolio (e.g., firms with blockbuster drugs may have more resources to avoid disclosure).
- **Physician Characteristics**: Test for heterogeneity by physician specialty (e.g., high-prescribing specialties like oncology) or geographic location (e.g., states with stricter disclosure laws).
- **Alternative Explanations**: The paper dismisses round-number clustering but does not test for it rigorously. Use a McCrary (2008) test to formally assess discontinuities at round numbers (e.g., $10, $15).

**Policy and Welfare:**
- **Cost of Avoidance**: Estimate the cost of avoiding disclosure (e.g., the foregone value of a $12 lunch vs. a $10 lunch) to quantify the welfare loss from strategic sizing.
- **Aggregate Threshold**: The paper notes that the aggregate threshold ($100/year) also censors payments, but this is not modeled. Discuss how the two thresholds interact (e.g., do manufacturers bunch just below $100 to avoid reporting any payments?).
- **International Comparison**: Compare the U.S. threshold to other countries’ disclosure rules (e.g., France’s €10 threshold, UK’s £25 threshold) to contextualize the welfare implications.

**Writing and Presentation:**
- **Figures**: The paper lacks visualizations of the key results. Include:
  - A histogram of payment amounts with the counterfactual overlaid (pooled and by year).
  - A plot of $\hat{b}$ over time with threshold values annotated.
  - A density plot comparing food/beverage vs. other payments.
- **Clarity**: The abstract and introduction overstate the findings. The paper measures a *density discontinuity*, not the "total volume of unreported payments." Clarify that the bunching estimate reflects the *marginal* censoring at the per-transaction threshold, not the full universe of unreported payments.
- **Literature**: Engage more deeply with the disclosure avoidance literature (e.g., Cain et al., 2005 on strategic disclosure; Sah and Frazzini, 2013 on conflict-of-interest reporting) and the bunching literature (e.g., Kleven and Waseem, 2013 on tax evasion).

**Minor Issues:**
- **Table 2**: The "Missing Mass" column is confusing (some values are negative, others positive). Clarify that this is the *excess mass count* (not normalized) and explain the sign convention.
- **Table 4**: The non-food estimate is implausibly large (10.76) with a huge SE (262.5). This suggests the polynomial is overfitting sparse data. Either drop this row or discuss why it is unreliable.
- **Section 5.3**: The discussion of "natural density decline" is redundant with the polynomial counterfactual. Focus on alternative explanations that the counterfactual does not address (e.g., manufacturer-level avoidance strategies).

**Conclusion:**
The paper’s core idea is novel and policy-relevant, but the execution falls short in sample representativeness, identification, and mechanism testing. With the above revisions—particularly addressing the sample limitations and leveraging the moving-threshold design—it could make a strong contribution to the literature on transparency mandates and disclosure avoidance.
